Research Study 19-2335
Using a within-subjects, double-blind, placebo (PLA)-controlled design, this study proposes to investigate the effects of tolcapone (TOLC) on brain activation associated with cognitive control (response inhibition), selective attention, and alcohol cue-reactivity, alcohol subjective effects, and risky decision-making after consumption of a standard drink among individuals with co-occurring Alcohol Use Disorder (AUD) and Attention-Deficit/Hyperactivity Disorder (ADHD).
This study evaluates the effects of an FDA-approved medication called tolcapone in people who have both Alcohol Use Disorder (AUD) and Attention-Deficit/Hyperactivity Disorder (ADHD). The study involves seven visits over a three to four week period, including an assessment visit and two eight-day medication periods during which participants will be assigned to take, in a double-blinded fashion, both tolcapone and a placebo (three visits during each period). During the study period there will be two fMRI scans and two on-campus alcohol administration sessions. Participants must not be seeking treatment for AUD or ADHD and must not be currently taking any psychotropic medications, including stimulant medications for ADHD.More
Age 21-65 and not currently seeking or engaged in treatment for Alcohol Use Disorder (AUD) or Attention-Deficit/Hyperactivity Disorder (ADHD).
Please contact the Translational Addiction Imaging Laboratory (TrAIL Lab) at firstname.lastname@example.org for more information about the study and additional eligibility criteria.
Brain Imaging Center (BIC)
Department Specific Free Standing Clinic
University of Colorado Hospital
Joseph Schacht, PhD
Protocol Number: 19-2335
More information available at ClinicalTrials.gov: NCT03904498
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers